Antoine E C, Rixe O, Vuillemin E, Benhammouda A, Borel C, Ghironzi G C, Mularoni E, Franks C, Auclerc G, Soubrane C
Department of Medical Oncology, Hôpital Pitié Salpêtrière, Paris, France.
Am J Clin Oncol. 1995 Oct;18(5):421-4. doi: 10.1097/00000421-199510000-00012.
Tamoxifen (TAM) has been reported to enhance cisplatin (CDDP) cytotoxicity in experimental and clinical melanoma studies. Based on our previous experience with sequential cisplatin-interleukin-2 (IL2)-interferon (IFN), we performed a phase II study of TAM combined with our original CDDP-IL2-IFN regimen in 22 pretreated metastatic melanoma patients. With a 41% response rate (95% CI, 21-61) we confirmed the interesting antitumor activity of CDDP-IL2-IFN combination; however, TAM enhanced neither the response rate nor the duration of response, but appeared to induce significantly more myelotoxicity, as compared to our previous results with CDDP-IL2-IFN alone. Whereas mechanisms by which TAM may modulate CDDP cytotoxicity in melanoma tumors remain unknown, the exact place of TAM, if any, and its safety in chemotherapeutic or chemoimmunotherapeutic combinations require further investigations.
在实验性和临床黑色素瘤研究中，已报道他莫昔芬（TAM）可增强顺铂（CDDP）的细胞毒性。基于我们之前使用顺铂-白细胞介素-2（IL2）-干扰素（IFN）序贯治疗的经验，我们对22例经预处理的转移性黑色素瘤患者进行了一项II期研究，将TAM与我们最初的CDDP-IL2-IFN方案联合使用。我们以41%的缓解率（95%置信区间，21-61）证实了CDDP-IL2-IFN联合方案有趣的抗肿瘤活性；然而，与我们之前单独使用CDDP-IL2-IFN的结果相比，TAM既未提高缓解率，也未延长缓解持续时间，反而似乎诱导了更明显的骨髓毒性。虽然TAM可能调节黑色素瘤肿瘤中CDDP细胞毒性的机制尚不清楚，但TAM在化疗或化疗免疫治疗联合方案中的确切作用（如果有的话）及其安全性仍需进一步研究。
